Author name: admingav

Survey participants will be entered into a raffle to receive a free Delegate registration for the EURETINA 2024 Congress in Barcelona and will receive a summary report before it is published. The sixth annual EURETINA Clinical Trends Survey is underway here in Amsterdam at the 2023 meeting. This survey builds upon the success of surveys

Gisbert Richard lecturer describes her 20+ year collaboration with engineering, computer science, and clinical colleagues and their ongoing journey to improve eye care through innovations in handheld and intraoperative OCT Without exclusion, retina specialists recognise the value brought by optical coherence tomography (OCT) to the care of patients with retinal disease. However, having access to

In his initial message inviting colleagues to the 23rd Euretina Congress in Amsterdam, Euretina President Alistair Laidlaw said, “Sustainability will once again be at the core of our conference organisation as we continue to measure and lower our carbon output.” “Euretina is committed to improving the sustainability of our Congress, and our objective is to

In the 2023 Kreissig Lecture, Professor Shwu-Jiuan Sheu MD, will outline the potential advantages and pitfalls of employing vitreretinal surgery as a management strategy for uveitis. In this interview, she discusses the key points she will raise in her lecture. What is driving the development of VR surgery as a management strategy for uveitis? There

A group of 69 applicants seeking to become the first recipients of the FEBOS-R completed the examination process on Wednesday 4th of October, the day before the start of the Euretina Congress. While registration for next year’s exams will not open until November, physicians interested in pursuing the FEBOS-R diploma can begin to prepare by

Ophthalmologica Award lecturer reviews the challenges faced in demonstrating the efficacy of investigational treatments for atrophic retinal diseases and possible solutions Geographic atrophy (GA) secondary to age-related macular degeneration (AMD), and Stargardt disease (STGD) are leading causes of blindness in the elderly and working-age populations, respectively. While no therapy for these diseases has yet been